Glaxo, Astellas duel for new place in anemia market; Novo Nordisk opens new U.S. HQ;

@FiercePharma: U.K. likely to pay for Avastin despite another NICE rejection. More | Follow @FiercePharma

@EricPFierce: Some popular drugs like Pradaxa, Prolia to be put through despised German price shredding formula. Story | Follow @EricPFierce

> Novo Nordisk ($NVO) opened a new U.S. headquarters in Plainsboro, N.J. Release

> Both GlaxoSmithKline ($GSK) and Japan's Astellas Pharma are working on pills for anemia to break into an $8 billion market targeted at injectable erythropoietin. Story

> Europe is looking to add environmental impact studies to evaluations of drugs. Report

> A watchdog group is asking regulators to look at the entire class of GLP-1 inhibitors for diabetes because of their link to a high number of cases of pancreatitis and pancreatic cancer. Report

> The South Korea-based biotech Celltrion has followed other drug developers in nixing late-stage development of a biosimilar version of Rituxan. Story

Medical Device News

@FierceMedDev: Hamburg: FDA is a bargain for taxpayers. Story | Follow @FierceMedDev

 @DamianFierce: LabCorp is slimming down and diversifying to stay profitable in a tough testing market. More | Follow @DamianFierce

> Intuitive Surgical's Q1 soars, despite da Vinci robot lawsuits. Article

> Covidien recalls ventilator batteries over failure risk. More

> Device company VC funding continues its plunge. Report

Biotech News

@FierceBiotech: Hear from top execs at Janssen talk about drug R&D, industry's drug pipeline efforts. More | Follow @FierceBiotech

@RyanMFierce: Biotech rattled as Q1 first-time VC deals plunge to 18-year low. News | Follow @RyanMFierce

> Pharma giants' oral EPO alternatives could cater to dopers. More

> Vertex skyrockets on positive Ph2 combo study in cystic fibrosis. Story

> Epizyme hits the biotech IPO queue with rapid R&D plan for cancer drugs. Report

And Finally... Cubist Pharmaceuticals ($CBST), which has said it is shooting for $2 billion in sales by 2017, reported its first quarter net income fell more than 80% after it paid $15 million to buy the rights to market an experimental antibiotic in more countries. Story